Overview

An Open-label, Parallel-group Study to Determine the Pharmacokinetics of a Single Dose of AFQ056 in Subjects With Renal Impairment Compared to Healthy Subjects

Status:
Completed

Trial end date:
2011-08-01

Target enrollment:

Participant gender:

Summary

The aim of this study was to characterize the pharmacokinetics and safety of AFQ056 in subjects with a different degree of renal impairment.

Phase:

Phase 1

Details

Lead Sponsor:

Novartis Pharmaceuticals